

**Question for written answer E-004349/2025
to the Commission**
Rule 144
Olivier Chastel (Renew)

Subject: Fighting cancer: cross-border clinical trial on combining mRNA COVID-19 vaccines and immunotherapy

A study by the University of Texas, presented on 19 October 2025 at the European Society of Medical Oncology Congress, shows that patients with advanced lung cancers or melanoma who received an mRNA vaccine against COVID-19 within 100 days of the start of their immunotherapy had their survival almost doubled compared to unvaccinated patients.

This finding comes in a context in which the EU invested heavily in the development and procurement of mRNA vaccines during the pandemic, demonstrating its capacity to coordinate when it comes to major public health challenges.

1. Does the Commission intend to support a Europe-wide clinical trial to assess the effectiveness of mRNA vaccination against COVID-19 in combination with immunotherapy, along the lines of the exceptional coordination implemented during the pandemic?
2. Could the establishment of derogations or accelerated procedures under Regulation (EU) No 536/2014 on clinical trials be envisaged for such a project of public interest?
3. Can the European Medicines Agency facilitate an accelerated scientific assessment procedure to extend the indication of existing mRNA vaccines to their use in combination with immunotherapy, given the already established safety profile of these vaccines and the urgent oncological need?

Submitted: 5.11.2025